Sharma Kamal, Sathe Sunil, Desai Bhupen, Manchanda Subhash, Mohan Jagdish, Bansal Manish, U M Nagamalesh, Oomman Abraham, Pande Arindam, Shah Jay, Christopher Johann, Patil Sachin, Abdullakutty Jabir, Bafna Akshay, Rao Sarita
Cardiology, SAL Hospital, Ahmedabad, IND.
Cardiology, Cardiac Care and Counselling Center, Pune, IND.
Cureus. 2025 Aug 7;17(8):e89579. doi: 10.7759/cureus.89579. eCollection 2025 Aug.
The cardiovascular continuum is the developmental process of cardiovascular diseases (CVDs) leading to heart failure (HF) and sudden cardiac death. Beta-blockers (BBs) are at the forefront of managing conditions along this continuum, ranging from cardiovascular (CV) risk factors to heart failure. In particular, bisoprolol proved to be a highly cardio-selective BB with a favourable pharmacokinetic profile, demonstrating long-term safety, good tolerability, and proven efficacy in reducing cardiac events, including arrhythmias and mortality in patients with heart failure with reduced ejection fraction (HFrEF). This evidence-based perspective showcased numerous clinical studies revealing the utility of bisoprolol in managing patients with CVDs, particularly HFrEF and stable angina. It also included safety evidence for bisoprolol in patients with renal and hepatic dysfunction, etc. Expert opinions from leading cardiologists across India further reinforce the role of bisoprolol as a first-line therapy in managing HFrEF and stable angina, making its usage suitable for HFrEF and angina patients with special emphasis on comorbidities, such as chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and diabetes.
心血管连续体是心血管疾病（CVD）发展为心力衰竭（HF）和心源性猝死的过程。β受体阻滞剂（BBs）在管理这一连续体上的各种病症方面处于前沿地位，涵盖从心血管（CV）危险因素到心力衰竭的范围。特别是，比索洛尔被证明是一种具有良好药代动力学特征的高度心脏选择性β受体阻滞剂，显示出长期安全性、良好耐受性，并在降低心脏事件（包括射血分数降低的心力衰竭（HFrEF）患者的心律失常和死亡率）方面具有已证实的疗效。这一基于证据的观点展示了众多临床研究，揭示了比索洛尔在管理CVD患者，特别是HFrEF和稳定型心绞痛患者方面的效用。它还包括比索洛尔在肾功能和肝功能不全等患者中的安全性证据。印度顶尖心脏病专家的专家意见进一步强化了比索洛尔作为管理HFrEF和稳定型心绞痛一线治疗药物的作用，使其适用于HFrEF和心绞痛患者，尤其着重于合并症，如慢性肾脏病（CKD）、慢性阻塞性肺疾病（COPD）和糖尿病患者。
